Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to June 2026, revenue grew 6.60%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
Johnson & Johnson (JNJ) EPS (diluted)
Johnson & Johnson's EPS (diluted) for fiscal 2025 was $11.03, up 90.5% from $5.79 in fiscal 2024. Over the twelve months to 30 June 2026 it was $8.63. Over the past ten years it has ranged from $0.47 (fiscal 2017) to $13.72 (fiscal 2023); the current reading is higher than 91% of that period. Johnson & Johnson ranks 3rd of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $11.03 | 90.50% |
| FY2024 | $5.79 | (57.80%) |
| FY2023 | $13.72 | 103.86% |
| FY2022 | $6.73 | (13.83%) |
| FY2021 | $7.81 | 41.74% |
| FY2020 | $5.51 | (2.13%) |
| FY2019 | $5.63 | 0.36% |
| FY2018 | $5.61 | 1,093.62% |
| FY2017 | $0.47 | (92.07%) |
| FY2016 | $5.93 | 8.21% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $2.27 | 6.07% |
| Mar 2026 | $2.14 | 1.90% |
| Dec 2025 | $2.10 | (0.94%) |
| Sep 2025 | $2.12 | (7.42%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LLY Eli Lilly and Company compare | $29.80 |
| AMGN Amgen Inc. compare | $16.09 |
| JNJ Johnson & Johnson | $8.63 |
| AZN AstraZeneca PLC compare | $6.69 |
| NVS Novartis AG compare | $6.63 |
| ABBV AbbVie Inc. compare | $3.54 |
| MRK Merck & Co., Inc. compare | $1.25 |
| PFE Pfizer Inc. compare | $0.76 |
| GILD Gilead Sciences, Inc. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on JNJ
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement